See every side of every news story
Get Started
SubscribeLogin
Pope Francis
Basketball
Vatican
Baseball
Donald Trump
Tennis
Hockey
Wrestling
Hamas
Israel-Hamas Conflict
Ukraine War
European Politics
Published • loading... • Updated

AGER-Dependent Macropinocytosis Drives Resistance to KRAS-G12D–Targeted Therapy in Advanced Pancreatic Cancer

Summary by Stemwell Science News
The authors found that advanced glycosylation end product–specific receptor (AGER) contributed to MRTX1133 resistance in PDAC through modulation of macropinocytosis and glutathione synthesis using patient-derived xenografts and orthotopic and genetically engineered mouse models. [Science Translational Medicine] Abstract
DisclaimerThis story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.

2 Articles

All
Left
Center
Right
rarecancernews.comrarecancernews.com

Lixumistat shows early promise as treatment for pancreatic cancer

Treatment with the once-daily oral therapy lixumistat, in addition to chemotherapy, slowed the growth of pancreatic cancer among participants with advanced disease in an early clinical trial, according to new data announced by lixumistat’s developer ImmunoMet Therapeutics. “Our study of lixumistat … in combination with [chemotherapy] shows quite encouraging clinical effects in this small … study,” Shubham Pant, MD, a trial investigator at the Un…

Read Full Article
Stemwell Science NewsStemwell Science News

AGER-Dependent Macropinocytosis Drives Resistance to KRAS-G12D–Targeted Therapy in Advanced Pancreatic Cancer

The authors found that advanced glycosylation end product–specific receptor (AGER) contributed to MRTX1133 resistance in PDAC through modulation of macropinocytosis and glutathione synthesis using patient-derived xenografts and orthotopic and genetically engineered mouse models. [Science Translational Medicine] Abstract

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • There is no tracked Bias information for the sources covering this story.
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

Stemwell Science News broke the news in on Thursday, January 30, 2025.
Sources are mostly out of (0)
Stories disproportionately reported by the Left or the Right

Similar News Topics

San Diego

San Diego

News
For You
Search
BlindspotLocal